Ebola may be slowing, but like most viruses it can return again in the future.

Whats really good about this story is, because of the Ebola issue, NanoLogix was able to use the sanctioned FDA fast tract to move the N-Assay through patent process in a shorter time span. When the N-Assay Patent is finally issued, Nanologix may be in a position to join forces with some other company/companies, who have the facilities to test for multiple viruses. Not just the Ebola virus.

So, I agree with you Shabby, doors may be opened for Nanologix that weren't there before the Ebola issue.